Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment
| Autor: | Helene N. Pena-Sahdala, Timothy C. Johnson, Saraswathi Gopal, Henry C. Bodenheimer, Pauline Suwandhi, Aaron E Walfish, David J. Clain, Kavitha Gopal, Christine T. Bang, Albert D. Min |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Genotype Hepacivirus Hepatitis C virus medicine.disease_cause Antiviral Agents Gastroenterology chemistry.chemical_compound Internal medicine Ribavirin medicine Humans Retrospective Studies Hepatology biology Cholesterol business.industry Hepatitis C Hepatitis C Chronic Middle Aged biology.organism_classification medicine.disease Lipoproteins LDL Treatment Outcome chemistry DNA Viral LDL receptor Immunology Drug Therapy Combination Female lipids (amino acids peptides and proteins) Interferons business Biomarkers Follow-Up Studies Lipoprotein |
| Zdroj: | Hepatology. 44:335-340 |
| ISSN: | 1527-3350 0270-9139 |
| DOI: | 10.1002/hep.21261 |
| Popis: | The low-density lipoprotein receptor (LDLR) has been proposed as a candidate receptor for the hepatitis C virus (HCV). Competitive inhibition of HCV binding to the LDLR by low-density lipoprotein (LDL) has been shown in vitro. If similar inhibition occurs in vivo, an elevated serum concentration of beta- lipoproteins may reduce the efficiency of infecting hepatocytes with HCV by competitively inhibiting HCV viral receptor binding. We investigated the role of baseline lipid values in influencing the outcome of HCV treatment. We conducted a retrospective chart review of patients treated with an interferon-based regimen at our liver and gastroenterology clinics between 1998 and 2004. Of 99 patients enrolled in the study, 49 (49.5%) had HCV genotype 1 (LDL 100.2 ± 30.2 mg/dL [mean ± SD]), and 50 patients (50.5%) had genotype 2 or 3 (LDL 110.1 ± 40 mg/dL) infection. Early viral response (EVR), end-of-treatment response (ETR), and sustained viral response (SVR) were documented in 99, 88, and 77 patients, respectively. LDL and cholesterol levels prior to treatment were found to be higher in patients with positive EVR, ETR, and SVR. This difference remained significant independent of age. Multivariate analysis controlling for genotype and age showed that the higher the cholesterol and LDL levels prior to treatment, the greater the odds of responding to treatment. In conclusion, having higher serum LDL and cholesterol levels before treatment may be significant prognostic indicators for treatment outcome of those with chronic hepatitis C infection, particularly in genotypes 1 and 2. (HEPATOLOGY 2006;44:335–340.) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text